Ranibizumab biosimilar (Xbrane)

雷珠单抗生物类似药 (Xbrane)

Report date: 2024/07/01 16:37:41

Base Information

Drug NameRanibizumab biosimilar (Xbrane)
Drug Alias Name雷珠单抗生物仿制药 (Xbrane)Ximluci
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetes ComplicationsWet age-related macular degenerationMacular Edema +[5] 
Global Approved IndicationsDiabetes ComplicationsWet age-related macular degenerationMacular Edema +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2022/11/09
Country/TerritoryCzechiaBulgariaUnited States +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesXbrane Biopharma Ab
China Registration ClassN/A

Develop Information

Active CompaniesXbrane Biopharma AbStada Arzneimittel Ag
Inactive CompaniesN/A
Active IndicationsDiabetes ComplicationsWet age-related macular degenerationMacular Edema +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeS01LA04
Related LinksN/A